-
Lion TCR Enrolls First Patient in LioCyx-M004 Study for HBV-Related Liver Cancer
•
Singapore-based clinical-stage biotech Lion TCR announced the enrollment of the first subject in a clinical study for LioCyx-M004, its autologous T-cell therapy targeting HBV-related hepatocellular carcinoma (HCC). The therapy uses mRNA-engineered T-cells to recognize and destroy hepatitis B virus (HBV)-related liver cancer cells. Therapy DetailsLioCyx-M004 leverages Lion TCR’s RNA technology…
-
Grand Pharma’s TLX591-CDx and TLX250-CDx Advance in China with NMPA Review
•
Grand Pharmaceutical Group Limited (HKG: 0512) announced that the National Medical Products Administration (NMPA) has accepted Investigational New Drug (IND) filings for TLX591-CDx (Illuccix) and TLX250-CDx, its radiopharmaceuticals for prostate cancer and clear cell renal cell carcinoma (ccRCC) diagnostics. Drug Profiles China Trials Global DevelopmentTLX591-CDx is filed for marketing in…
-
OriginCell Therapeutics Raises USD 120M in Series B for Tumor Immunotherapy Pipeline
•
OriginCell Therapeutics, a Shanghai-based tumor immunotherapy specialist, reportedly raised over USD 120 million in a Series B financing round. The round was co-led by Qiming Venture Partners and Quan Capital, with participation from Shanghai Science and Technology Innovation Center Equity Investment Fund, Sinopharm Capital, Suzhou Fund, Boquan Equity Investment Management,…
-
Fosun Pharma to Hike Aitrox Stake to 72.63% for USD 61M
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) plans to increase its ownership of Aitrox from 28.23% to 72.63% in a deal valued at RMB 412.35 million (USD 61 million). The investment includes a direct capital injection of RMB 50 million (USD 7.4 million) and the acquisition of…
-
GluBio Pharma Raises USD 22M in Series A+ Round to Advance TPD Pipeline
•
GluBio Pharmaceutical Co., Ltd, a Zhejiang-based specialist in molecular glue targeted protein degradation (TPD), reportedly raised USD 22 million in a Series A+ financing round. The round brings the company’s total funding to USD 90 million since its founding in March 2023. Existing investor Qiming Venture Partners led the round,…
-
BridGene Biosciences Completes USD 38.5M Series B Round with China Funds
•
U.S.-based biotech BridGene Biosciences Inc. has completed a Series B financing round, raising USD 38.5 million. The round was backed by China-based funds, including Beijing’s Lapam Capital, Hong Kong’s Junson Capital, and Xiamen’s Dyee Capital. Funding UseProceeds will support the development of BridGene’s proprietary chemoproteomic platform IMTAC, including clinical trials…
-
Basecare Medical Sells 35% Stake in Cellpro Biotech for USD 9.5M
•
Suzhou Basecare Medical Co., Ltd (HKG: 2170), a China-based IVF specialist, will sell a 35% stake in its assisted reproductive product developer Zhejiang Cellpro Biotech Co., Ltd for RMB 64.17 million (USD 9.5 million). Post-deal, Basecare will retain a 15% stake in Cellpro, having previously acquired 51% of the firm…
-
Sanjin Pharma’s Subsidiary Gets FDA Nod for BC007 Cancer Drug Trial
•
China-based Guilin Sanjin Pharmaceutical Co. Ltd (SHE: 002275) announced that its subsidiary, Dragon Boat Pharmaceutical (Shanghai) Co., Ltd, has received approval from the U.S. Food and Drug Administration (FDA) to conduct a Phase I clinical study of BC007, a bispecific antibody (BsAb) targeting CLDN18.2 and CD47, in patients with solid…
-
Pica Partners with BrainCo to Launch ADHD Product in China
•
Shanghai-based primary healthcare digital platform Pica, developed by Wuxi AppTec in 2016, has partnered with BrainCo, a firm operating in China and the U.S., to launch the latter’s ADHD product in China. Financial details of the deal were not disclosed. Product DetailsThe ADHD product features a smart, non-invasive brain-computer interface…
-
Innovent and Laekna Dose First Patient in Afuresertib and Tyvyt Study for PD-1 Resistant Tumors
•
China’s Innovent Biologics Inc. (HKG: 1801) and partner Laekna Therapeutics Shanghai Co., Ltd announced that the first patient has been dosed in a Phase I/II clinical study (NCT05383482) evaluating afuresertib combined with Tyvyt (sintilimab) plus chemotherapy in solid tumors resistant to PD-1/PD-L1 inhibitors. Study DetailsThe multi-center, single-arm, open-label, dose-escalation study…
-
Dongcheng Pharmaceutical Gets NMPA Green Light for PSMA PET Imaging Drug
•
China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) announced it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for a radioactive in vivo diagnostic drug. The drug is intended for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)-positive lesions in…
-
CanSino Biologics Launches Menhycia Meningococcal Vaccine in Six Provinces
•
China-based CanSino Biologics (HKG: 6185) announced the launch of its ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4, trade name: Menhycia), marking the debut of China’s first quadrivalent meningococcal conjugate vaccine. The vaccine is now available in Anhui, Shandong, Fujian, Guangxi, Heilongjiang, and Yunnan. Vaccine DetailsMenhycia covalently binds to meningococcal serogroups A,…
-
Mabwell Bioscience Gets FDA Approval for Nectin-4 ADC 9MW2821 in Solid Tumors
•
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced it has received approval from the U.S. Food and Drug Administration (FDA) to conduct a clinical study of its antibody drug conjugate (ADC) 9MW2821, targeting Nectin-4, in solid tumors. The drug is the first of its kind to enter clinical trials…
-
LaNova Medicines Gets FDA Green Light for LM-305 Myeloma Study
•
Shanghai-based cancer therapy developer LaNova Medicines Ltd announced it has received approval from the U.S. Food and Drug Administration (FDA) to conduct an open-label, multi-center Phase I/II study of LM-305, an antibody drug conjugate (ADC) targeting GPRC5D, in patients with multiple myeloma (MM). Drug ProfileLM-305 is the first GPRC5D-targeting ADC…
-
Sanofi’s Q2 Earnings Show 8.1% Global Sales Growth, Led by Dupixent and China Expansion
•
France-based Sanofi (NASDAQ: SNY) reported Q2 2022 global sales of EUR 10.1 billion (USD 10.3 billion), marking an 8.1% year-on-year (YOY) increase in constant exchange rate (CER) terms. Growth was driven by the anti-allergy drug Dupixent (dupilumab) and strong performances in rare diseases, vaccines, and consumer healthcare. Pharmaceuticals and Vaccines…
-
CSPC Pharmaceutical’s Albumin-Bound Docetaxel Receives Orphan Drug Designation for Gastric Cancer
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received an orphan drug designation (ODD) from the National Medical Products Administration (NMPA) for its docetaxel (albumin-bound) in gastric cancer, including esophagogastric junction cancer. Product ProfileThe product uses innovative human albumin encapsulation technology to deliver docetaxel nanoparticles into the…
-
Kira Pharmaceuticals’ KP104 Receives Orphan Drug Designation for PNH Treatment
•
Sino-US biotech Kira Pharmaceuticals announced that it has received an Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for KP104, its first-in-class biologic for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). Drug ProfileKP104 is a bifunctional biologic designed to selectively block the alternative and terminal pathways…
-
Merck’s Q2 Sales Surge 31% to USD 14.6B, Led by Keytruda and China Growth
•
US-based Merck, Sharp & Dohme (MSD, NYSE: MRK) reported Q2 2022 global sales of USD 14.6 billion, marking a 31% increase in constant exchange rate (CER) terms. The growth was driven by recovery from COVID-19 disruptions and contributions from the COVID-19 antiviral drug Lagevrio (molnupiravir). Key Growth Drivers China PerformanceChina…
-
Takeda’s Alunbrig Prescribed in China for ALK+ NSCLC Treatment
•
Japan-based Takeda Pharmaceutical Co., Ltd (TYO: 4502) announced that its lung cancer therapy Alunbrig (brigatinib) has been prescribed in China for the first time, marking its official commercialization and clinical application in the country. The drug was approved in March 2023 to treat anaplastic lymphoma kinase (ALK)-positive locally advanced or…
